/U P D A T E -- MediPharm Labs Corp./

Core Viewpoint - MediPharm Labs Corp. is preparing for its Annual and Special Meeting of Shareholders on June 16, 2025, emphasizing the importance of shareholder support for its Board of Directors and strategic direction amidst a challenge from a dissident shareholder [1][2][6]. Financial Performance - In 2024, MediPharm reported a 27% year-over-year increase in net revenue and improved gross profit margin from 18% in 2023 to 31% [5]. - The company's Adjusted EBITDA loss narrowed by $8.3 million to $1.9 million in 2024 compared to the previous year, with expectations of reaching positive Adjusted EBITDA soon [5]. Strategic Developments - MediPharm has undergone a strategic revitalization, including the acquisition of VIVO Cannabis in March 2023, which has opened new international markets and contributed approximately $10 million in annual revenue from its Beacon brand in Australia [12][13]. - The company has streamlined operations, focusing on strategic business lines and reducing operating expenses by half through synergies from the VIVO acquisition [11][13]. Governance and Shareholder Engagement - The Board of Directors recommends shareholders vote using the GREEN proxy to support its nominees, highlighting concerns about the qualifications of dissident nominees from Apollo Technology Capital Corp. [2][6][16]. - MediPharm emphasizes its commitment to good governance practices, including an independent Chair and key committees, to enhance shareholder value [20][21]. Market Position and Future Outlook - MediPharm's product mix includes various cannabis products, with international sales exceeding 50% of revenues in recent quarters, positioning the company for growth in the medical cannabis sector [15]. - The company believes it has established a solid foundation for future growth and is committed to ongoing enhancements in governance and operational strategies [28][27].